Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:BGMNASDAQ:GLUENASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$7.68-1.0%$8.00$4.71▼$10.67$1.05B1.21.35 million shs346 shsBGMQilian International Holding Group$10.39+7.7%$10.34$5.26▼$14.78$1.03B1.3226,748 shs128,761 shsGLUEMonte Rosa Therapeutics$4.31-2.3%$5.61$3.21▼$12.40$245.73M1.531.03 million shs1.08 million shsSNDXSyndax Pharmaceuticals$11.19-1.3%$13.51$9.66▼$25.07$974.02M1.281.57 million shs952 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+0.26%+7.64%-5.02%+0.78%+53.77%BGMQilian International Holding Group+8.70%-0.10%+7.81%+10.42%+1,048,999,900.00%GLUEMonte Rosa Therapeutics+0.45%+13.01%-29.35%-29.01%-32.57%SNDXSyndax Pharmaceuticals+0.80%+7.29%-12.51%-11.48%-47.59%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.5698 of 5 stars3.51.00.00.03.20.81.9BGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/AGLUEMonte Rosa Therapeutics3.1069 of 5 stars3.43.00.00.03.63.30.6SNDXSyndax Pharmaceuticals3.3516 of 5 stars3.51.00.04.43.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5049.84% UpsideBGMQilian International Holding Group 0.00N/AN/AN/AGLUEMonte Rosa Therapeutics 2.75Moderate Buy$15.50259.63% UpsideSNDXSyndax Pharmaceuticals 2.90Moderate Buy$36.20223.65% UpsideCurrent Analyst Ratings BreakdownLatest GLUE, AUPH, SNDX, and BGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025GLUEMonte Rosa TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $10.003/20/2025GLUEMonte Rosa TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.003/20/2025SNDXSyndax PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$39.00 ➝ $41.003/12/2025GLUEMonte Rosa TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$19.003/4/2025SNDXSyndax PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$35.00 ➝ $39.003/4/2025SNDXSyndax PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $42.003/4/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M4.48N/AN/A$2.63 per share2.92BGMQilian International Holding Group$25.10M40.25N/AN/A$6.10 per share1.70GLUEMonte Rosa Therapeutics$75.62M3.51N/AN/A$3.58 per share1.20SNDXSyndax Pharmaceuticals$23.68M40.64N/AN/A$6.53 per share1.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M$0.05N/A13.71N/A-10.23%-4.41%-3.07%5/1/2025 (Estimated)BGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AGLUEMonte Rosa Therapeutics-$135.35M-$1.02N/AN/AN/AN/A-62.68%-38.83%5/8/2025 (Estimated)SNDXSyndax Pharmaceuticals-$209.36M-$3.73N/AN/AN/AN/A-64.34%-57.72%5/6/2025 (Estimated)Latest GLUE, AUPH, SNDX, and BGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GLUEMonte Rosa Therapeutics-$0.24N/AN/AN/A$13.57 millionN/A5/6/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.2419N/AN/AN/A$15.88 millionN/A5/1/2025Q1 2025AUPHAurinia Pharmaceuticals$0.09N/AN/AN/A$61.06 millionN/A3/20/2025Q4 2024GLUEMonte Rosa Therapeutics-$0.37$0.23+$0.60$0.23$43.73 million$14.00 million3/3/2025Q4 2024SNDXSyndax Pharmaceuticals-$0.31-$1.10-$0.79-$1.10$86.32 million$7.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ABGMQilian International Holding GroupN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.175.605.11BGMQilian International Holding GroupN/A3.392.82GLUEMonte Rosa TherapeuticsN/A6.036.03SNDXSyndax PharmaceuticalsN/A6.996.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%BGMQilian International Holding GroupN/AGLUEMonte Rosa Therapeutics79.96%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals4.30%BGMQilian International Holding Group58.66%GLUEMonte Rosa Therapeutics6.50%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300137.34 million137.02 millionOptionableBGMQilian International Holding Group29897.22 million2.48 millionN/AGLUEMonte Rosa Therapeutics9061.51 million57.44 millionOptionableSNDXSyndax Pharmaceuticals11086.04 million81.86 millionOptionableGLUE, AUPH, SNDX, and BGM HeadlinesRecent News About These CompaniesSei Investments Co. Sells 35,414 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 14 at 3:13 AM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Raised to "Sell" at StockNews.comApril 12, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6% - Here's What HappenedApril 11, 2025 | marketbeat.comExodusPoint Capital Management LP Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 11, 2025 | marketbeat.comSyndax price target lowered to $19 from $33 at BarclaysApril 10, 2025 | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month Low - Here's WhyApril 9, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 8, 2025 | marketbeat.comRhenman & Partners Asset Management AB Sells 27,500 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 7, 2025 | marketbeat.comBryce Point Capital LLC Invests $417,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 7, 2025 | marketbeat.comTrexquant Investment LP Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 7, 2025 | marketbeat.comWellington Management Group LLP Trims Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 7, 2025 | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 4.7% - Here's WhyApril 4, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Raised to Sell at StockNews.comApril 3, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year Low - Here's What HappenedApril 2, 2025 | marketbeat.comSyndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology ForumApril 2, 2025 | globenewswire.comAxiom Investors LLC DE Reduces Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 2, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.5% - What's Next?April 1, 2025 | marketbeat.comSimplify Asset Management Inc. Buys 25,456 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)March 24, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading 5.5% Higher on Analyst UpgradeMarch 21, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $41.00March 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLUE, AUPH, SNDX, and BGM Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$7.68 -0.08 (-0.97%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Qilian International Holding Group NASDAQ:BGM$10.39 +0.74 (+7.67%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Monte Rosa Therapeutics NASDAQ:GLUE$4.31 -0.10 (-2.27%) As of 09:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Syndax Pharmaceuticals NASDAQ:SNDX$11.18 -0.15 (-1.28%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock is a Buy as Cyberthreat Environment Expands 2 Penny Stocks With $10 Potential Congress! Who Traded What During the Tariff-Induced Meltdown Beware of BigBear.ai: Insiders Are Selling—Should You? NATO Deal Sparks 4% Jump in Palantir Stock—What’s Next? Microsoft: A Blend of Growth and Value Amid Tariff Concerns Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
